Clearing aged cells may boost stem cell therapies

Mesenchymal stem cells (MSCs) are connective-tissue cells that secrete repair-promoting factors. They have been studied for years as a therapy for fibrosis, organ damage, and chronic inflammation. But clinical results have frequently disappointed. One possible reason: aging tissues are filled with senescent cells, which secrete a mix of inflammatory and tissue-degrading molecules known as the SASP (senescence-associated secretory phenotype). This hostile environment may actively suppress transplanted stem cells.

In the study, published in the Journal of Translational Medicine and associated with biotech startup Immorta Bio, researchers tested two acute mouse models of organ damage: one using a liver toxin, one using a low-dose chemotherapy drug that drives cells into senescence. Four groups were compared: untreated, MSCs alone, a senolytic vaccine (SenoVax) alone, or the combination.

Combination outperforms on every measure

On inflammation markers and organ function, the combination consistently outperformed either treatment alone. Four inflammatory markers in the liver model all dropped most sharply in the combination group. The findings sound compelling, but important caveats apply. Both models involve acute, artificially induced injury rather than natural aging. It is unknown whether the same effects would occur in animals that simply grow old. There is also an inconsistency in how SenoVax is described: in the study it is presented as a simple peptide-based vaccine, while the company’s patent and press materials describe a more complex personalised cellular immunotherapy.

A plausible idea that needs independent testing

The core hypothesis is scientifically sound. If SASP factors from senescent cells suppress stem cell function, clearing them first is a logical preparatory step. Prior research has confirmed that SASP can inhibit stem cell proliferation and survival. Whether this works in humans undergoing natural aging requires larger, independent studies in models that more closely replicate how we actually grow old.

Read the original article